HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patients.
Georgios PapatheodoridisKonstantinos MimidisSpilios ManolakopoulosChristos TriantosIoannis VlachogiannakosChristos VeretanosMelanie DeutschStylianos KaratapanisIoannis GoulisIoannis ElefsiniotisEvangelos CholongitasVassilios SevastianosDimitrios ChristodoulouDimitrios SamonakisEmanuel ManesisAndreas KapataisNikolaos PapadopoulosPanagiota IoannidouGeorgios GermanidisGeorge GiannoulisDimitra LakiotakiDionysios KogiasΗarikleia KranidiotiKonstantinos ZisimopoulosMaria MelaGeorge KontosParaskevi FytiliChrysanthi ManolakaPolyxeni AgorastouSpyridon I PantziosMargarita PapatheodoridiDimitrios KaragiannakisEleni GeladariNikolaos PsychosKalliopi ZachouAnna ChalkidouAnastasia SpanoudakiKonstantinos ThomopoulosGeorgios N DalekosPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
Anti-HDV screening rates and recall capabilities vary widely among Greek liver clinics being higher in HBsAg-positive patients of known risk group with active/advanced liver disease seen at smaller centres, while non-medical factors are also important. Anti-HDV prevalence varies throughout Greece being higher in patients born abroad with younger age, parenteral drug use and advanced liver disease. Viremia is more frequently but not exclusively detected in anti-HDV-positive patients with elevated ALT and advanced liver disease.